# AstraZeneca beat first-quarter sales and profit expectations.

*biotech · news · 2026-04-29 · MarketScreener*

## Key points

- AstraZeneca's Q1 core earnings were $2.58 per share, beating analyst expectations of $2.54.
- Total Q1 revenue reached $15.29 billion, surpassing the consensus estimate of $14.9 billion.
- AstraZeneca is maintaining its 2026 financial outlook despite geopolitical and industry challenges.
- Cancer drug demand and investments in the U.S. and China are driving AstraZeneca's growth.

**Companies:** AstraZeneca
**Countries:** United States, China, United Kingdom

[Read the full story on MarketScreener](https://www.marketscreener.com/news/astrazeneca-beats-profit-expectations-keeps-annual-outlook-unchanged-ce7f59d3dd88f72c)

---

Canonical: https://newsio.io/n/c6795384-0c88-417b-99c5-080835353f26/astrazeneca-beat-first-quarter-sales-and-profit-expectations-companys-core-earni
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works